Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deferasirox in Adult Allogeneic HSCT Recipients With Iron Overload
NCT00602446Phase 2Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Aug 2007
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of deferasirox in Transfusional Iron Overload (TIO), sponsored by Masonic Cancer Center. Primary endpoint: Number of Patients Not Completing Treatment at 6 months. Started Aug 2007; status: terminated.
02
Drugs
deferasirox
03
Conditions
Transfusional Iron Overload (TIO)
Beyond the preview
Go deeper on NCT00602446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00602446.